FDA tracker: Novel approvals in pediatrics during 2026

Multiple strides in pediatric care have been reported so far in 2026, marking a transformative year for the treatment of rare pediatric disorders and chronic dermatologic conditions. From the first targeted therapy for neurologic complications in Hunter syndrome and novel interventions for ultrarare diseases such as Menkes disease and arginase 1 deficiency, to historic firsts in oral and topical treatments for plaque psoriasis and atopic dermatitis in children and adolescents, clinical innovation is rapidly expanding the therapeutic tool kit available to pediatricians.